Think It's Too Late to Buy This Leading Biotech Stock? Here's Why There's Still Time.

The market was less than impressed with the top-line results from Viking Therapeutics' (NASDAQ: VKTX) phase 2 trial of an oral formulation of its anti-obesity drug VK2735. The disappointment created the sense that the stock lacks any near-term catalysts -- phase 3 results from VK2735 in subcutaneous (injection) form aren't likely until 2027 -- and that the excitement around the stock was primarily centered on the oral formulation.However, that reaction may prove too hasty, and there's still time to buy into the healthcare stock.Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool